GTBP GT Biopharma, Inc.
$5.50▲ +8.38%
Healthcare
Other
Volume 36.6K
Avg Volume (10D) 75.0K
Key Metrics & Fundamentals
Market Cap
$11.33M
P/E Ratio
0.0
Div Yield
0.00%
52W Range
4.91 - 28.75
% vs 50 MA
4.87%
% vs 200 MA
199.95%
RSI-14
43.5
MACD Histogram
-0.2900
Beta (1Y vs SPY)
1.60
Free Cash Flow
-$2.47M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$2.78M
COGS
–
Operating Exp
$2.85M
Operating Income
-$2.85M
EBIT
-$2.85M
Pretax Income
-$2.83M
Net Income
-$2.83M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting
GlobeNewswire · Oct 26, 2026 8:00 AM ET
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
Benzinga · Sep 16, 2026 7:30 AM ET
GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma
GlobeNewswire · Sep 15, 2026 9:15 AM ET
EXCLUSIVE: GT Biopharma Achieves Development Milestone for Human Trial for Novel Blood Cancer Therapy
Benzinga · Sep 15, 2026 8:45 AM ET
GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026
GlobeNewswire · Sep 11, 2026 8:00 AM ET
GT Biopharma Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 14, 2026 8:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See GTBP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.